Literature DB >> 10435266

Adding a choice-based program for tobacco smoking to an abstinence-based addiction treatment program.

S M Bernstein1, G Stoduto.   

Abstract

A smoking program that provides awareness education about smoking to all chemical dependency (CD) clients and staff, while allowing treatment for smoking to be optional, was developed at an abstinence-based addiction treatment center. This study measured the effects of introducing this mixed model for treatment of smoking and other substances on clients and staff. Attitude and program utilization data were collected, and CD clients were followed-up. The value of offering a smoking program during CD treatment and of framing it within a choice-based philosophy was strongly endorsed by staff and CD clients. Smoking program CD clients did not report major problems with other clients continuing to smoke. Most (55.6%) of the staff who smoked (n = 18) entered the smoking program during the first year of implementation; 38.0% of CD clients who smoked (n = 424) actively joined the smoking program; and of CD clients who chose cessation, 17.5% were abstinent at follow-up.

Entities:  

Mesh:

Year:  1999        PMID: 10435266     DOI: 10.1016/s0740-5472(98)00071-3

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  10 in total

Review 1.  Staff smoking and other barriers to nicotine dependence intervention in addiction treatment settings: a review.

Authors:  Joseph Guydish; Emma Passalacqua; Barbara Tajima; Sarah Turcotte Manser
Journal:  J Psychoactive Drugs       Date:  2007-12

2.  Measuring smoking knowledge, attitudes and services (S-KAS) among clients in addiction treatment.

Authors:  Joseph Guydish; Barbara Tajima; Mable Chan; Kevin L Delucchi; Doug Ziedonis
Journal:  Drug Alcohol Depend       Date:  2010-11-04       Impact factor: 4.492

3.  Substance abuse counselors' implementation of tobacco cessation guidelines.

Authors:  Tanja C Rothrauff; Lillian T Eby
Journal:  J Psychoactive Drugs       Date:  2011 Jan-Mar

4.  Addressing Tobacco Through Organizational Change (ATTOC) in residential addiction treatment settings.

Authors:  Joseph Guydish; Douglas Ziedonis; Barbara Tajima; Greg Seward; Emma Passalacqua; Mable Chan; Kevin Delucchi; Lucy Zammarelli; Michael Levy; Monika Kolodziej; Greg Brigham
Journal:  Drug Alcohol Depend       Date:  2011-09-08       Impact factor: 4.492

5.  Development of the Smoking Knowledge, Attitudes, and Practices (S-KAP) Instrument.

Authors:  Kevin L Delucchi; Barbara Tajima; Joseph Guydish
Journal:  J Drug Issues       Date:  2009-03

6.  Addressing tobacco use through organizational change: a case study of an addiction treatment organization.

Authors:  Douglas M Ziedonis; Lucy Zammarelli; Gregory Seward; Karen Oliver; Joseph Guydish; Marie Hobart; Bruce Meltzer
Journal:  J Psychoactive Drugs       Date:  2007-12

7.  Substance abuse counselor certification in California: how is nicotine addiction addressed?

Authors:  Keiko Kurita; Joseph Guydish
Journal:  J Psychoactive Drugs       Date:  2007-12

8.  Factors associated with nicotine dependence during methadone maintenance treatment: findings from a multisite survey in Vietnam.

Authors:  Huyen Phuc Do; Long Hoang Nguyen; Nhung Phuong Thi Nguyen; Chau Ngo; Huong Lan Thi Nguyen; Giang Tong Le; Linh Khanh Nguyen; Cuong Tat Nguyen; Bach Xuan Tran; Huong Thi Le; Thuc Minh Thi Vu; Huong Thu Thi Phan; Tho Dinh Tran; Carl A Latkin; Michael P Dunne
Journal:  BMJ Open       Date:  2017-07-17       Impact factor: 2.692

9.  Is treatment outcome improved if patients match themselves to treatment options? Study protocol for a randomized controlled trial.

Authors:  Morten Ellegaard Hell; William R Miller; Bent Nielsen; Anette Søgaard Nielsen
Journal:  Trials       Date:  2018-04-06       Impact factor: 2.279

Review 10.  Patient Preferences and Shared Decision Making in the Treatment of Substance Use Disorders: A Systematic Review of the Literature.

Authors:  Anke Friedrichs; Maren Spies; Martin Härter; Angela Buchholz
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.